Skip to main content

Table 3 Hospitalizations for RSV-related conditions among fully prophylaxed and partially prophylaxed infants*

From: Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis

Measure

Fully prophylaxed infants (N= 2828)

Partially prophylaxed infants (N= 5615)

p-value (fully versus partially prophylaxed)

 

Number/mean

Percent/SD

Number/mean

Percent/SD

 

Number of infants with ≥1 in-season hospitalization

222

7.9%

658

11.7%

<0.001

Mean hospitalizations among patients with at least 1 hospitalization

1.3

0.6

1.3

0.7

1.000

Age (days) at first admission

180.4

71.3

174.7

66.4

0.278

Mean length of stay (days)

4.5

3.2

6.4

7.4

<0.001

Number of infants admitted to ICU or receiving mechanical ventilation or supplemental oxygen

12

6.3%

83

16.8%

<0.001

RSV hospitalizations per 100 seasons

10.0

40.3

14.5

54.7

<0.001

  1. *Includes all infants in study population (N= 8443); first palivizumab dose may have occurred prior to or during RSV season.
  2. RSV season= October 1 through April 30.
  3. Season rate calculation= (Number of infants with RSV hospitalization in 210 days after first dose or between first dose through April 30, whichever comes first) divided by (days evaluated divided by 210) times 100. We assumed an RSV season of October-April which corresponds to 210 days.